Beractant
Survanta (beractant) is an unknown pharmaceutical. Beractant was first approved as Survanta on 1991-07-01. It is used to treat newborn respiratory distress syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Survanta
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| survanta | Biologic Licensing Application | 2022-07-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| newborn respiratory distress syndrome | — | D012127 | P22 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
beractant, Survanta, AbbVie Inc. | |||
| 2098-07-02 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 4 | 4 | 4 | 3 | 12 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 1 | 4 | 4 | 4 | 3 | 12 |
| Syndrome | D013577 | — | — | 1 | 3 | 2 | 2 | 1 | 6 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | 1 | 1 | 2 | 4 |
| Bronchopulmonary dysplasia | D001997 | — | P27.8 | — | 1 | 1 | 1 | 1 | 3 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | 1 | — | 2 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | — | 1 | — | 1 |
| Patent ductus arteriosus | D004374 | HP_0001643 | Q25.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Birth weight | D001724 | EFO_0004344 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyaline membrane disease | D006819 | EFO_1000644 | P22.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Beractant |
| INN | — |
| Description | Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids,
fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome. Survanta is manufactured by Abbvie.
|
| Classification | Small molecule |
| Drug class | pulmonary surfactants; tachykinin (neurokinin) receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 108778-82-1 |
| RxCUI | 46967 |
| ChEMBL ID | CHEMBL1201624 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06761 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 788 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
361 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use